Abstract: The current study suggests that circulating total- and LDL-cholesterol levels potentially may be linked to the factor(s) influencing PD risk. Further studies to validate these results would impact our understanding of the role of cholesterol as a risk factor in PD, and its relationship to recent public health controversies.
Introduction
The relationship between cholesterol and Parkinson’s Disease (PD) has long been a subject of clinical debate. While high cholesterol is a well-known risk factor for cardiovascular disease, a "cholesterol paradox" appears in the context of neurodegeneration: higher plasma cholesterol levels have been associated with lower PD prevalence, slower disease progression, and better cognitive outcomes. This study, published in Frontiers in Neurology, investigates whether lower levels of circulating total- and LDL-cholesterol are significantly linked to an increased risk of PD, potentially challenging the assumption that cholesterol-lowering interventions are universally neuroprotective.
Methods and Data
The researchers analyzed data from the NINDS PD Biomarkers Program (PDBP) cohort, consisting of 91 PD patients and 70 age- and gender-matched controls. To address potential confounding factors such as smoking, statin use, and genetic variants, the study employed a two-step causal inference framework:
- Generalized Propensity Score Approach: A Marginal Structural Model (MSM) was used to estimate the effect of continuous cholesterol exposure while controlling for observed confounders.
- Statistical Modeling: Linear regression estimated how factors like age, gender, and specific genetic polymorphisms (APOE, LDLR, LRP1, LRPAP1) influenced cholesterol levels. These scores were then used to weight subjects, effectively balancing the groups for analysis.
- Genotyping: DNA analysis focused on SNPs in genes known to manage cholesterol transport and metabolism.
Key Insights
A significant finding was the role of the LRP1 gene as a driver of circulating cholesterol levels. LRP1 is involved in lipid delivery to neurons and amyloid-beta clearance, suggesting a shared biological pathway between systemic lipid metabolism and neurodegenerative processes.
Furthermore, the study addressed the impact of statins. While statin use naturally lowers cholesterol, the model indicated that the resulting lower cholesterol levels—regardless of the cause—were associated with PD. This suggests that peripheral LDL particles or oxysterols might influence the cholesterol-rich environment of the brain more directly than previously assumed.
Results
The analysis revealed several key findings:
- Lower Cholesterol in PD: Total cholesterol (183.0 vs. 195.2 mg/dL) and LDL-cholesterol (108.4 vs. 118.5 mg/dL) were significantly lower in PD patients compared to controls.
- Causal Association: Propensity score analysis linked lower total cholesterol (p < 0.001) and LDL-cholesterol (p = 0.04) to PD occurrence.
- Odds Ratios: For every 1 mg/dL increase in cholesterol, the odds of having PD decreased by approximately 2-3% (OR: 0.97 for total cholesterol; 0.98 for LDL).
- Non-Significant Factors: HDL-cholesterol and triglycerides did not show a significant influence on PD risk in this specific model.
Conclusion and Future Directions
While the statistical link is robust, the underlying mechanism remains to be fully elucidated. It is unclear whether low cholesterol directly impairs neuronal membrane integrity or serves as a proxy for other metabolic dysfunctions. The study's limitations include a relatively small sample size (n=161) and a narrow genetic focus. Future research should expand to larger cohorts and broader polygenic risk scores to determine if maintaining "higher-normal" cholesterol levels could serve as a protective strategy against Parkinson's Disease.
Summary updated